Since the efficacy of checkpoint therapy is linked to the neoantigen load and NU7441 increased neoantigen expression, we investigated the ability for NU-SL40 to enhance the antitumor activity of combination treatment with anti–PD-1/–CTLA-4 in mice bearing an established B16-F10 tumor. This evidence concerns the gene CTLA4 and neoplasm.